Top > Search of International Patents > Antiviral agent, abzyme, primer set, method for producing polynucleotide, and method for producing polypeptide

Antiviral agent, abzyme, primer set, method for producing polynucleotide, and method for producing polypeptide

Foreign code F170009182
File No. AF12-05WO
Posted date Sep 12, 2017
Country United States of America
Application number 201113579529
Gazette No. 20120322135
Gazette No. 9365637
Date of filing Feb 21, 2011
Gazette Date Dec 20, 2012
Gazette Date Jun 14, 2016
International application number JP2011053752
International publication number WO2011102517
Date of international filing Feb 21, 2011
Date of international publication Aug 25, 2011
Priority data
  • P2010-034998 (Feb 19, 2010) JP
  • P2010-035021 (Feb 19, 2010) JP
  • P2010-092461 (Apr 13, 2010) JP
  • 2011WO-JP53752 (Feb 21, 2011) WO
Title Antiviral agent, abzyme, primer set, method for producing polynucleotide, and method for producing polypeptide
Abstract (US9365637)
The present invention provides: a novel antiviral agent containing a human antibody κ light chain, a novel human abzyme containing a human antibody κ light chain; a polynucleotide, a vector, and a transformant, encoding a human antibody κ light chain of the above; a primer set for effectively obtaining a human antibody κ light chain having a function as an antiviral agent or abzyme; and a method for producing a polynucleotide and a method for producing a polypeptide, each of which method utilizes the primer set.
Scope of claims [claim1]
1. A human abzyme comprising one of the following (a) through (f): (a) a human antibody kappa (kappa ) light chain with a variable domain consisting of SEQ ID NO: 26, and a constant domain with an Ala in the position corresponding to Cys219 in the amino acid sequence shown in SEQ ID NO: 24;
(b) a human antibody kappa (kappa ) light chain with a variable domain consisting of SEQ ID NO: 14, and a constant domain with an Ala in the position corresponding to Cys220 in the amino acid sequence shown in SEQ ID NO: 1;
(c) a human antibody kappa (kappa ) light chain with a variable domain consisting of SEQ ID NO: 50, and a constant domain with an Ala in the position corresponding to Cys220 in the amino acid sequence shown in SEQ ID NO: 48;
(d) a human antibody kappa (kappa ) light chain with a variable domain consisting of SEQ ID NO: 35, and a constant domain with an Ala in the position corresponding to Cys219 in the amino acid sequence shown in SEQ ID NO: 33;
(e) a human antibody kappa (kappa ) light chain with a variable domain consisting of SEQ ID NO: 54, and a constant domain with an Ala in the position corresponding to Cys219 in the amino acid sequence shown in SEQ ID NO: 52; or
(f) a human antibody kappa (kappa ) light chain with a variable domain consisting of SEQ ID NO: 22, and a constant domain with an Ala in the position corresponding to Cys219 in the amino acid sequence shown in SEQ ID NO: 20.
[claim2]
2. The human abzyme as set forth in claim 1, wherein: the human abzyme has an anti rhabdovirus activity, and anti influenza virus activity; and
the variable domain consists of SEQ ID NO: 26,
the constant domain has an Ala in the position corresponding to Cys219 in the amino acid sequence shown in SEQ ID NO: 20.
[claim3]
3. The human abzyme as set forth in claim 1, wherein: the human abzyme has an anti rhabdovirus activity, anti influenza virus activity, and cytotoxicity against cancer cells; and
the variable domain consists SEQ ID NO: 14,
the constant domain has an Ala in the position corresponding to Cys220 in the amino acid sequence shown in SEQ ID NO: 1.
[claim4]
4. The human abzyme as set forth in claim 1, wherein: the human abzyme has an anti influenza virus activity and nucleolytic activity; and
the variable domain consists of SEQ ID NO: 50,
the constant domain has an Ala in the position corresponding to Cys220 in the amino acid sequence shown in SEQ ID NO: 48.
[claim5]
5. The human abzyme as set forth in claim 1, wherein: the human abzyme has an anti influenza virus activity; and
the variable domain consists of SEQ ID NO: 35,
the constant domain has an Ala in the position corresponding to Cys219 in the amino acid sequence shown in SEQ ID NO: 33.
[claim6]
6. The human abzyme as set forth in claim 1, wherein: the human abzyme has an anti influenza virus activity; and
the variable domain consists of SEQ ID NO: 54,
the constant domain has an Ala in the position corresponding to Cys219 in the amino acid sequence shown in SEQ ID NO: 52.
[claim7]
7. The human abzyme as set forth in claim 1, wherein: the human abzyme has an anti rhabdovirus activity; and
the variable domain consists of SEQ ID NO: 22,
the constant domain has an Ala in the position corresponding to Cys219 in the amino acid sequence shown in SEQ ID NO: 20.
[claim8]
8. A method for treating a patient of a rhabdovirus infectious disease by administering a human abzyme comprising a human antibody kappa (kappa ) light chain with a variable domain consisting of SEQ ID NO: 26, 14, 30, or 22 to the patient, wherein the administering does not comprise administering a human antibody heavy chain.
[claim9]
9. A method for treating a patient of an influenza virus infectious disease by administering a human abzyme comprising a human antibody kappa (kappa ) light chain with a variable domain consisting of SEQ ID NO: 26, 14, 50, 35 or 54 to the patient.
  • Inventor, and Inventor/Applicant
  • UDA TAIZO
  • HIFUMI EMI
  • NISHIZONO AKIRA
  • ARAKAWA MITSUE
  • JAPAN SCIENCE AND TECHNOLOGY AGENCY
IPC(International Patent Classification)
Reference ( R and D project ) CREST Establishment of Innovative Manufacturing Technology Based on Nanoscience AREA
Please contact us by E-mail or facsimile if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close